Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onglyza in drug-naive type 2 diabetes
NCT00698932Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2008
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Saxagliptin 5mg with Placebo (2 arms). Primary endpoint: Glycosylated Haemoglobin A1c at 24 weeks. Started Jun 2008; status: completed.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00698932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00698932.